Administrative Core
行政核心
基本信息
- 批准号:10380820
- 负责人:
- 金额:$ 18.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-04 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAdvocateBioinformaticsBiological Specimen BanksBiometryBiotechnologyClinicalClinical TrialsCommunicationCommunitiesConflict (Psychology)DataDevelopmentElectronic MailEnrollmentEnsureEvaluation ResearchFamilyFamily PhysiciansFred Hutchinson Cancer Research CenterFundingGoalsHuman ResourcesImmuneImmunobiologyImmunooncologyImmunophenotypingImmunotherapyInformation DisseminationInstitutionInterest GroupLaboratoriesLeadershipLogisticsMaintenanceMerkel cell carcinomaMissionPatient RecruitmentsPatientsPersonsPhysiciansPlayPrivacyProgram SustainabilityProgress ReportsRegulationReportingResearchResearch PersonnelResolutionResource SharingResourcesRoleScheduleServicesSourceSpecimenStrategic PlanningT-LymphocyteTeleconferencesTimeTransgenic OrganismsUnited States National Institutes of HealthUniversitiesVisitWashingtoncancer careconflict resolutiondata repositorymeetingsmembernoveloperationorganizational structureoutreachpatient safetyperformance siteprogramsweb site
项目摘要
ADMINISTRATIVE CORE
PROJECT SUMMARY
The Administrative Core of the “Immunobiology and Immune Therapy for Merkel cell carcinoma” P01 provides
overall direction, coordination of the Scientific Advisory Board meetings, as well as administrative, regulatory
and fiscal oversight to the three Projects and the three Shared Resource Cores (Biostatistics & Bioinformatics,
Immunophenotyping, and Specimen & Data). The Administrative Core will provide an effective organizational
structure to expedite research and promote communication between Program Project components and
investigators and the scientific and patient communities. The Administrative Core is responsible for strategic
planning, as well as effective organizational structure among the performance sites (Fred Hutchinson Cancer
Research Center, University of Washington, and Seattle Cancer Care Alliance). The Administrative Core is
responsible for research effort coordination and allocation of NIH funds. This Core will also manage fiscal
components of the Program Project including reallocation of funds to optimize overall function, and resolution
of potential conflicts in a fair and equitable manner to maximize progress of the Program. The Administrative
Core is responsible for communication including dissemination of information relevant to the Program via
email, GoToMeeting teleconferences, as well as in-person meetings. In addition, The Core will provide
strategic outreach to the patient, physician, and scientific communities through maintenance of the
merkelcell.org website (which reaches 100,000 unique users each year), coordination with our MCC patient
advocates, and organization of the MCC Multicenter Interest Group annual meeting. The mission of this Core
is to ensure regulatory and administrative compliance including reporting to the Scientific Advisory Boards and
NIH as well as to support and sustain optimal efficiency of the Projects and Cores of the Program.
行政核心
项目概要
“默克尔细胞癌的免疫生物学和免疫治疗”P01的管理核心提供
总体指导、科学顾问委员会会议的协调以及行政、监管
对三个项目和三个共享资源核心(生物统计和生物信息学、
免疫表型分析、样本和数据)。行政核心将提供有效的组织。
加快研究并促进计划项目组成部分和
行政核心负责战略。
规划以及表演场所之间有效的组织结构(弗雷德·哈钦森癌症
研究中心、华盛顿大学和西雅图癌症护理联盟)。
该核心负责国家卫生研究院资金的研究工作协调和分配。
该计划项目的组成部分,包括重新分配资金以优化整体功能和决议
以公平公正的方式解决潜在冲突,以最大限度地推进该计划。
核心负责沟通,包括通过以下方式传播与计划相关的信息:
此外,The Core 还将提供电子邮件、GoToMeeting 电话会议以及现场会议。
通过维护患者、医生和科学界的战略外展
merkelcell.org 网站(每年有 100,000 名独立用户),与我们的 MCC 患者协调
MCC 多中心兴趣小组年会的倡导者和组织 该核心的使命。
是为了确保监管和行政合规性,包括向科学顾问委员会报告和
NIH 以及支持和维持项目和计划核心的最佳效率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL NGHIEM其他文献
PAUL NGHIEM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL NGHIEM', 18)}}的其他基金
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
10629189 - 财政年份:2019
- 资助金额:
$ 18.77万 - 项目类别:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
项目 2:描述和克服对 PD-1 阻断疗法无反应的问题
- 批准号:
10629191 - 财政年份:2019
- 资助金额:
$ 18.77万 - 项目类别:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
10380816 - 财政年份:2019
- 资助金额:
$ 18.77万 - 项目类别:
Immunobiology and Immune Therapy for Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
9906874 - 财政年份:2019
- 资助金额:
$ 18.77万 - 项目类别:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
项目 2:描述和克服对 PD-1 阻断疗法无反应的问题
- 批准号:
10380818 - 财政年份:2019
- 资助金额:
$ 18.77万 - 项目类别:
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin
紫外线诱导的皮肤 DNA 损伤反应和致癌机制
- 批准号:
9038985 - 财政年份:2015
- 资助金额:
$ 18.77万 - 项目类别:
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma
默克尔细胞癌改进治疗的发病机制和预后研究
- 批准号:
8699412 - 财政年份:2014
- 资助金额:
$ 18.77万 - 项目类别: